These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22696123)

  • 21. Gray matter involvement in multiple sclerosis.
    Pirko I; Lucchinetti CF; Sriram S; Bakshi R
    Neurology; 2007 Feb; 68(9):634-42. PubMed ID: 17325269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical-magnetic resonance imaging correlations in multiple sclerosis.
    Zivadinov R; Leist TP
    J Neuroimaging; 2005; 15(4 Suppl):10S-21S. PubMed ID: 16385015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammation high-field magnetic resonance imaging.
    Kilsdonk ID; de Graaf WL; Barkhof F; Wattjes MP
    Neuroimaging Clin N Am; 2012 May; 22(2):135-57, ix. PubMed ID: 22548925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.
    Bakshi R; Dandamudi VS; Neema M; De C; Bermel RA
    J Neuroimaging; 2005; 15(4 Suppl):30S-45S. PubMed ID: 16385017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.
    Bagnato F; Ohayon JM; Ehrmantraut M; Chiu AW; Riva M; Ikonomidou VN
    Expert Rev Neurother; 2006 Apr; 6(4):599-612. PubMed ID: 16623658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetisation transfer imaging in multiple sclerosis.
    Filippi M; Rovaris M
    J Neurovirol; 2000 May; 6 Suppl 2():S115-20. PubMed ID: 10871798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measuring brain atrophy in multiple sclerosis.
    De Stefano N; Battaglini M; Smith SM
    J Neuroimaging; 2007 Apr; 17 Suppl 1():10S-15S. PubMed ID: 17425728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
    Ziemann U; Wahl M; Hattingen E; Tumani H
    Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
    Zivadinov R
    Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast enhancement and the acute lesion in multiple sclerosis.
    Rovaris M; Filippi M
    Neuroimaging Clin N Am; 2000 Nov; 10(4):705-16 ,viii-ix. PubMed ID: 11359720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Magnetic resonance in the diagnosis and treatment of multiple sclerosis].
    Rovira Cañellas A
    Neurologia; 2000; 15(7):288-302. PubMed ID: 11075577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study.
    Sinnecker T; Mittelstaedt P; Dörr J; Pfueller CF; Harms L; Niendorf T; Paul F; Wuerfel J
    Arch Neurol; 2012 Jun; 69(6):739-45. PubMed ID: 22351849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.
    Tortorella C; Bellacosa A; Paolicelli D; Fuiani A; Di Monte E; Simone IL; Giaquinto P; Livrea P; Trojano M
    J Neurol Sci; 2005 Dec; 239(1):95-9. PubMed ID: 16209877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
    Barkhof F; van Walderveen M
    Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1675-86. PubMed ID: 10603619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis.
    Inglese M; Benedetti B; Filippi M
    J Neurol Sci; 2005 Jun; 233(1-2):15-9. PubMed ID: 15949493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cortical pathology and cognitive impairment in multiple sclerosis.
    Calabrese M; Rinaldi F; Grossi P; Gallo P
    Expert Rev Neurother; 2011 Mar; 11(3):425-32. PubMed ID: 21375447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
    Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
    J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.